Immunotherapy for bladder cancer.

Intravesical immunotherapy in nonmuscle invasive bladder cancer. Indian J Urol (2015) 0.79

Development of new immunotherapy treatments in different cancer types. J Med Life (2016) 0.77

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol (2017) 0.75

Local Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy. Sci Rep (2016) 0.75

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors. Urol Ann (2016) 0.75

Immunotherapy in urothelial carcinoma: fade or future standard? Transl Androl Urol (2016) 0.75

The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Front Immunol (2017) 0.75

Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 14.96

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49

Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 9.66

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol (1976) 4.37

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol (2000) 4.28

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol (2009) 4.17

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol (2012) 4.08

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol (2002) 4.08

Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol (2014) 3.65

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology (2004) 2.64

Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis (1999) 2.50

A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat (2005) 2.44

BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol (2003) 2.30

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol (2007) 2.15

Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis (2000) 2.07

Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol (2013) 2.02

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int (2013) 1.87

Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol (2009) 1.87

Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol (2009) 1.86

A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol (2007) 1.85

The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol (2006) 1.81

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother (2006) 1.81

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol (2012) 1.75

Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol (2011) 1.71

Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66

Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol (2009) 1.59

The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol (2014) 1.48

Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy. J Urol (2013) 1.43

Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol (2014) 1.42

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest (1990) 1.42

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol (2006) 1.42

Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest (1993) 1.38

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol (1980) 1.29

Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol (2008) 1.25

T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol (1993) 1.24

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int (2013) 1.24

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res (2004) 1.23

NK cells are essential for effective BCG immunotherapy. Int J Cancer (2001) 1.19

Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol (2001) 1.18

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15

Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol (1995) 1.14

Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol (1996) 1.14

Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol (1997) 1.10

Photodynamic therapy for urological malignancies: past to current approaches. J Urol (2006) 1.07

Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol (2001) 1.05

Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release (2004) 1.03

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci (2013) 1.03

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int (2002) 1.02

What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol (2000) 1.01

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol (2007) 0.99

Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol (1996) 0.98

Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg (1998) 0.94

Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol (2009) 0.94

Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol (1988) 0.93

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev (2011) 0.93

Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. J Photochem Photobiol B (1998) 0.92

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology (2003) 0.91

Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res (1992) 0.91

IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol (2010) 0.91

Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res (1997) 0.90

Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells. Int J Urol (2002) 0.90

Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol (2001) 0.90

BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw (1998) 0.90

In vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCG. Vaccine (2011) 0.88

Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol (2010) 0.87

Virus therapy for bladder cancer. Cytokine Growth Factor Rev (2010) 0.86

Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL). Urol Oncol (2012) 0.86

Toll-like receptors in urothelial cells--targets for cancer immunotherapy. Nat Rev Urol (2013) 0.85

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol (2012) 0.85

Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep (1985) 0.85

Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol (2006) 0.84

Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Int J Urol (2007) 0.84

Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol (2011) 0.84

Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol (2001) 0.84

Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation (2003) 0.84

Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. Clin Exp Immunol (2014) 0.84

Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J Urol (2002) 0.83

Use of bacillus Calmette-Guérin in stage T1 bladder cancer: Long-term observation of a population-based cohort. Scand J Urol (2014) 0.83

Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J Control Release (2013) 0.82

Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder. Br J Cancer (1995) 0.81

Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer. Br J Urol (1996) 0.81

Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol (1998) 0.81

Bacterial modulation of antigen processing and presentation. Microbes Infect (2000) 0.80

Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology (2001) 0.78

Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin. BJU Int (2008) 0.78

Photodynamic therapy in urology: what can we do now and where are we heading? Photodiagnosis Photodyn Ther (2012) 0.76